Management of hepatitis B reactivation in patients receiving cancer chemotherapy

Therapeutic Advances in Gastroenterology

Volumn 5, Issue 5, 2012, Pages 359-370

  Huang, Yi Wen ^a   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer; Chemotherapy; HBV reactivation; Hepatitis B virus; Lamivudine; Prophylaxis

Indexed keywords

ADEFOVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RITUXIMAB; TELBIVUDINE; TENOFOVIR;

ANTIBODY SCREENING; CANCER CHEMOTHERAPY; CELLULAR IMMUNITY; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DNA REPAIR; FULMINANT HEPATIC FAILURE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TREATMENT DURATION; VIRUS REACTIVATION;

EID: 84870437729     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X12450245     Document Type: Article

References (79)

1. Alexopoulos C.G. Vaslamatzis M. Hatzidimitriou G. (1999) Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 81: 69–74.
2. Artz A.S. Somerfield M.R. Feld J.J. Giusti A.F. Kramer B.S. Sabichi A.L. et al. (2010) American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28: 3199–3202.
3. Chang T.T. Gish R.G. de Man R. Gadano A. Sollano J. Chao Y.C. et al. (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001–1010.
4. Cheng J.C. Liu M.C. Tsai S.Y. Fang W.T. Jer-Min Jian J. Sung J.L. (2004) Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients. Cancer 101: 2126–2133.
5. Cheng A.L. Hsiung C.A. Su I.J. Chen P.J. Chang M.C. Tsao C.J. et al. (2003) Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37: 1320–1328.
6. Chung Y.L. Tsai T.Y. (2009) Promyelocytic leukemia nuclear bodies link the DNA damage repair pathway with hepatitis B virus replication: implications for hepatitis B virus exacerbation during chemotherapy and radiotherapy. Mol Cancer Res 7: 1672–1685.
7. Cortelezzi A. Vigano M. Zilioli V.R. Fantini N.N. Pasquini M.C. Deliliers G.L. et al. (2006) Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol 35: 467–469.
8. Dai M.S. Lu J.J. Chen Y.C. Perng C.L. Chao T.Y. (2001) Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients. Cancer 92: 2927–2932.
9. Dai M.S. Chao T.Y. Kao W.Y. Shyu R.Y. Liu T.M. (2004 a) Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 83:769–774.
10. Dai M.S. Wu P.F. Lu J.J. Shyu R.Y. Chao T.Y. (2004 b) Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer 12: 191–196.
11. Dai M.S. Wu P.F. Shyu R.Y. Lu J.J. Chao T.Y. (2004 c) Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 24: 540–546.
12. Day F.L. Karnon J. Rischin D. (2011) Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 29: 3270–3277.
13. el-Sayed M.H. Shanab G. Karim A.M. el-Tawil A. Black A. Dixon J.S. (2004) Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with hematological malignancies: a preliminary report. Pediatr Hematol Oncol 21: 145–156.
14. Galbraith R.M. Eddleston A.L. Williams R. Zuckerman A.J. (1975) Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2: 528–530.
15. Hoofnagle J.H. (2009) Reactivation of hepatitis B. Hepatology 49: S156-S165.
16. Hsu C. Hsiung C.A. Su I.J. Hwang W.S. Wang M.C. Lin S.F. et al. (2008) A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 47: 844–853.
17. Hsu C. Sur I.J. Hwang W.S. Wang M.C. Lin S.F. Lin T.H. et al. (2006) A prospective comparative study of prophylactic or therapeutic use of lamivudine for chemotherapy-associated hepatitis B (HBV) reactivation in non-Hodgkin's lymphoma patients [Abstract]. Gastroenterology 131: S297.
18. Hui C.K. Cheung W.W. Au W.Y. Lie A.K. Zhang H.Y. Yueng Y.H. et al. (2005) Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 54: 1597–1603.
19. Hui C.K. Cheung W.W. Zhang H.Y. Au W.Y. Yueng Y.H. Leung A.Y. et al. (2006) Kinetics and risk of de novo hepatitis B infection in H Bs Ag-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131: 59–68.
20. Hwang J.P. Fisch M.J. Zhang H. Kallen M.A. Routbort M. Lal L.S. et al. (2011) Reactivation of hepatitis B infection among patients with cancer [Abstract]. Hepatology 54: 445A.
21. Idilman R. Arat M. Soydan E. Toruner M. Soykan I. Akbulut H. et al. (2004) Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 11: 141–147.
22. Jang J.W. Choi J.Y. Bae S.H. Kim C.W. Yoon S.K. Cho S.H. et al. (2004) Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 41: 427–435.
23. Jang J.W. Choi J.Y. Bae S.H. Yoon S.K. Chang U.I. Kim C.W. et al. (2006) A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 43: 233–240.
24. Ji D. Cao J. Hong X. Li J. Wang J. Chen F. et al. (2010) Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are H Bs Ag-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol 85: 243–250.
25. Jia J. Lin F. (2004) Lamivudine therapy for prevention of chemotherapy-induced reactivation of hepatitis B virus. Zhonghua Gan Zang Bing Za Zhi 12: 628–629.
26. Kim M.K. Ahn J.H. Kim S.B. Im Y.S. Lee S.I. Ahn S.H. et al. (2007) Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. Korean J Intern Med 22: 237–243.
27. Kim S.G. Chun J.M. Jin R. Kim J.Y. Won D.I. Hwang Y.J. (2010) Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc 42: 843–845.
28. King L.Y. Chung R.T. (2010) When treating cancer, please don't forget hepatitis B. Oncologist 15: 826–829.
29. Kohrt H.E. Ouyang D.L. Keeffe E.B. (2006) Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 24: 1003–1016.
30. Koo Y.X. Tan D.S. Tan I.B. Tao M. Chow W.C. Lim S.T. (2010) Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 116: 115–121.
31. Koo Y.X. Tay M. The Y.E. Teng D. Tan D.S. Tan I.B. et al. (2011) Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 90: 1219–1223.
32. Kumagai K. Takagi T. Nakamura S. Sawada U. Kura U. Kodama F. et al. (1997) Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 8(Suppl. 1): 107–109.
33. Lau G.K. Yiu H.H. Fong D.Y. Cheng H.C. Au W.Y. Lai L.S. et al. (2003) Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125: 1742–1749.
34. Leaw S.J. Yen C.J. Huang W.T. Chen T.Y. Su W.C. Tsao C.J. (2004) Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 83: 270–275.
35. Lee G.W. Ryu M.H. Lee J.L. Oh S. Kim E. Lee J.H. et al. (2003) The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 18: 849–854.
36. Li H.R. Huang J.J. Guo H.Q. Zhang X. Xie Y. Zhu H.L. et al. (2011) Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 18: 877–883.
37. Li Y.H. He Y.F. Jiang W.Q. Wang F.H. Lin X.B. Zhang L. et al. (2006) Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 106: 1320–1325.
38. Liang R.H. Lok A.S. Lai C.L. Chan T.K. Todd D. Chiu E.K. (1990) Hepatitis B infection in patients with lymphomas. Hematol Oncol 8: 261–270.
39. Lim L.L. Wai C.T. Lee Y.M. Kong H.L. Lim R. Koay E. et al. (2002) Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 16: 1939–1944.
40. Lok A.S. McMahon B.J. (2009) Chronic hepatitis B: update 2009. Hepatology 50: 661-662 (http://www.aasld.org).
41. Loomba R. Rowley A. Wesley R. Liang T.J. Hoofnagle J.H. Pucino F. et al. (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148: 519–528.
42. Martyak L.A. Taqavi E. Saab S. (2008) Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 28: 28–38.
43. Maruyama T. Iino S. Koike K. Yasuda K. Milich D.R. (1993) Serology of acute exacerbation in chronic hepatitis B virus infection. Gastroenterology 105: 1141–1151.
44. Matsue K. Kimura S. Takanashi Y. Iwama K. Fujiwara H. Yamakura M. et al. (2010) Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD 20-positive B-cell lymphoma. Cancer 116: 4769–4776.
45. Mendez-Navarro J. Corey K.E. Zheng H. Barlow L.L. Jang J.Y. Lin W. et al. (2011) Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 31: 330–339.
46. Nagamatsu H. Itano S. Nagaoka S. Akiyoshi J. Matsugaki S. Kurogi J. et al. (2004) Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 99: 2369–2375.
47. Nagamatsu H. Kumashiro R. Itano S. Matsugaki S. Sata M. (2003) Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res 26: 293–301.
48. Nair P.V. Tong M.J. Stevenson D. Roskamp D. Boone C. (1986) A pilot study on the effects of prednisolone withdrawal on serum hepatitis B virus DNA and HBeAg in chronic active hepatitis B. Hepatology 6: 1319–1324.
49. Nakamura Y. Motokura T. Fujita A. Yamashita T. Ogata E. (1996) Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer 78: 2210–2215.
50. Noterdaeme T. Longree L. Bataille C. Deroover A. Lamprove A. Delwaide J. et al. (2011) Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients. World J Gastroenterol 17: 3069–3072.
51. Ohtsu T. Sai T. Oka M. Shgai Y. Tobinai K. (1991) Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Japan J Clin Oncol 21: 360–365.
52. Pelizzari A.M. Motta M. Cariani E. Turconi P. Borlenghi E. Rossi G. (2004) Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J 5: 325–328.
53. Perez-Roldan F. Gonzalez-Carro P. Villafanez-Garcia M.C. (2005) Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med 352: 310–311.
54. Persico M. de Marino F. Russo G.D. Morante A. Rotoli B. Torella R. et al. (2002) Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 99: 724–725.
55. Pinto P.C. Hu E. Bernstein-Singer M. Pinter-Brown L. Govindarajan S. (1990) Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 65: 878–884.
56. Rossi G. Pelizzari A. Motta M. Puoti M. (2001) Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic Hbs Ag carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 115: 58–62.
57. Saab S. Dong M.H. Joseph T.A. Tong M.J. (2007) Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology 46: 1049–1056.
58. Shibolet O. Ilan Y. Gillis S. Hubert A. Shouval D. Safadi R. (2002) Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100: 391–396.
59. Sorrell M.F. Belongia E.A. Costa J. Gareen I.F. Grem J.L. Inadomi J.M. et al. (2009) National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 49: S4-S12.
60. Steinberg J.L. Yeo W. Zhong S. Chan J.Y. Tam J.S. Chan P.K. et al. (2000) Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol 60: 249–255.
61. Sugimoto R. Enjoji M. Kotoh K. Noguchi K. Tsuruta S. Nakamuta M. et al. (2004) Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy. Fukuoka Igaku Zasshi 95: 274–279.
62. Tsutsumi Y. Shigematsu A. Hashino S. Tanaka J. Chiba K. Masauzi N. et al. (2009) Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido. Ann Hematol 88: 375–377.
63. Vassiliadis T. Garipidou V. Tziomalos K. Perifanis V. Giouleme O. Vakalopoulou S. (2005) Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy – a prospective case series. Am J Hematol 80: 197–203.
64. Wands J.R. Chura C.M. Roll F.J. Maddrey W.C. (1975) Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68: 105–112.
65. Weinbaum C.M. Mast E.E. Ward J.W. (2009) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology 49: S35-S44.
66. Xunrong L. Yan A.W. Liang R. Lau G.K. (2001) Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy – pathogenesis and management. Rev Med Virol 11: 287–299.
67. Yeo W. Chan P.K.S. Chan H.L.Y. Mo F.K.F. Johnson P.J. (2001) Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 65: 473–477.
68. Yeo W. Chan P.K.S. Ho W.M. Zee B. Lam K.C. Lei K.I. et al. (2004 a) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22: 927–934.
69. Yeo W. Chan P.K.S. Hui P. Ho W.M. Lam K.C. Kwan W.H. et al. (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70: 553–561.
70. Yeo W. Chan T.C. Leung N.W.Y. Lam W.Y. Mo F.K.F. Chu M.T. et al. (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27: 605–611.
71. Yeo W. Chan P.K.S. Zhong S. Ho W.M. Steinberg J.L. Tam J.S. et al. (2000 a) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62: 299–307.
72. Yeo W. Ho W.M. Hui P. Chan P.K. Lam K.C. Lee J.J. et al. (2004 b) Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 88: 209–215.
73. Yeo W. Hui E.P. Chan A.T.C. Ho W.M. Lam K.C. Chan P.K.S. et al. (2005) Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 28: 379–384.
74. Yeo W. Lam K.C. Zee B. Chan P.S.K. Mo F.K.F. Ho W.M. et al. (2004 c) Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 15: 1661–1666.
75. Yeo W. Zee B. Zhong S. Chan P.K.S. Wong W.L. Ho W.M. et al. (2004 d) Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90: 1306–1311.
76. Yeo W. Zhong S. Chan P.K. Ho W.M. Wong H.T. Chan A.S. et al. (2000 b) Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy. J Viral Hepat 7: 448–458.
77. Yun J. Kim K.H. Kang E.S. Gwak G.Y. Choi M.S. Lee J.E. et al. (2011) Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer 104: 559–563.
78. Zhong S. Yeo W. Schroder C. Chan P.K. Wong W.L. Ho W.M. et al. (2004) High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 11: 55–59.
79. Ziakas P.D. Karsaliakos P. Mylonakis E. (2009) Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 94: 998–1005.